Purpose To review outcomes following microwave ablation (MWA) of colorectal cancer pulmonary metastases and assess predictors of oncologic outcomes. Methods Technical success, primary and secondary technique efficacy rates were evaluated for 50 patients with 90 colorectal cancer pulmonary metastases at immediate, 4-8 weeks post-MWA and subsequent follow-up CT and/ or 18 F-FDG PET/CT. Local tumor progression (LTP) rate, LTP-free survival (LTPFS), cancer-specific and overall survivals were assessed. Complications were recorded according to SIR classification. Results Median follow-up was 25.6 months. Median tumor size was 1 cm (0.3-3.2 cm). Technical success, primary and secondary technique efficacy rates were 99, 90 and 92%, respectively. LTP rate was 10%. One-, 2-and 3-year LTPFS were: 93, 86 and 86%, respectively, with median LTPFS not reached. Median overall survival was 58.6 months, and median cancer-specific survival (CSS) was not reached. One-, 2-and 3-year overall and CSS were 94% and 98, 82 and 90%, 61 and 70%, respectively. On univariate analysis, minimal ablation margin (p \ 0.001) and tumor size (p = 0.001) predicted LTPFS, with no LTP for minimal margin C 5 mm and/or tumor size \ 1 cm. Pleural-based metastases were associated with increased LTP risk (p = 0.002, SHR = 7.7). Pre-MWA CEA level [ 10 ng/ml (p = 0.046) and C 3 prior chemotherapy lines predicted decreased CSS (p = 0.02). There was no 90-day death. Major complications rate was 13%. Conclusions MWA with minimal ablation margin C 5 mm is essential for local control of colorectal cancer pulmonary metastases. Pleural-based metastases and larger tumor size were associated with higher risk of LTP. CEA level and pre-MWA chemotherapy impacted CSS.
Introduction
Approximately 5% of men and 4% of women develop colorectal cancer (CRC) during their lifetime, with 20% of patients having distant metastases at initial diagnosis [1, 2] . Lung is the second most common metastatic site with I. Kurilova and A. Gonzalez-Aguirre have contributed equally to this work.
10-15% lung metastases incidence [3, 4] . Five-year survival of patients with distant disease is roughly 12% [5] . Complete metastatectomy and/or ablation increase 5-year survival to 27-68% [6] [7] [8] [9] . However, only minority of patients with CRC pulmonary metastases are surgical candidates due to comorbidities or compromised pulmonary function [10] . In addition, recurrences after lung metastasectomy are common (20-68%) and subsequent surgery is challenging due to limited pulmonary reserve [11] [12] [13] [14] . Key ablation advantages compared to surgery include the ability to preserve pulmonary parenchyma and lung function and retreat new and recurrent metastases that are common in this population [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . Ablation is commonly used in the treatment of patients with limited number of relatively small tumors. Preferably \ 3 tumors in each hemithorax with no, limited or at least controlled extrapulmonary disease are generally accepted pulmonary ablation eligibility criteria [26] [27] [28] [29] .
Microwave ablation (MWA) has at least theoretical potential to overcome known limitations of radiofrequency ablation (RFA) [20, 21, 25-28, 30, 31] , such as the diminished thermal conductivity of aerated lung and the ''heat sink phenomenon'' (due to flow in nearby vessels or airway) that can impact the ability to create large and more uniform ablation zones with adequate margins and in shorter time, as demonstrated in animal studies [32] [33] [34] [35] . Consequently, higher rates of complete ablation and sustained tumor control could be expected when using MWA [33] [34] [35] .
This study assessed oncologic outcomes and complications of MWA in the management of patients with colorectal pulmonary metastases as well as factors affecting these outcomes.
Methods Study Population
IRB waiver of approval was obtained for this retrospective review of our prospectively created and maintained HIPAA registered and compliant lung tumor ablation database. All patients with colorectal pulmonary metastases undergoing image-guided MWA between March 2011 and May 2016 were included in the study.
MWA inclusion criteria were: limited number of metastases (up to 6) in each hemithorax and relatively small tumor size (up to 3.5 cm) with no, limited or at least controlled extrapulmonary disease. Central tumor location was not an exclusion criterion if ablation could be performed safely without risk of damaging adjacent structures. The decision to treat metastasis with ablation was made after multidisciplinary discussion.
Ablation Procedure, Imaging Follow-Up and Definitions
Operators' experience, pre-ablation imaging and biopsy timing, image guidance, percutaneous entry route, MWA system and electrode choice, prophylactic antibiotics, anesthesia type, bilateral lung metastases and pneumothorax management, thermal monitoring, immediate postprocedure imaging, minimal ablation margin measurement ( Fig. 1 ) and imaging follow-up are described in Table 1 . All study definitions are described in Table 2 .
All patients with LTP were assessed for repeat thermal ablation eligibility. Fig. 1 Minimal ablation margin measurement. A pre-ablation measurements: measurement (1) = 34 mm; measurement (2) = 14 mm; measurement (3) = 8 mm; measurement (4) = 50 mm. B Post-ablation measurements: measurement (1) = 19 mm; measurement (2) = 12 mm; measurement (3) = 3 mm; measurement (4) = 37 mm. After subtracting corresponding measurements at each location [1] [2] [3] [4] , the respective ablation margins were 15, 2, 5 and 13 mm. Therefore, minimal ablation margin for this ablation zone was 2 mm (insufficient). C Minimal ablation margin scheme
Study Objectives
Primary objectives included technical success, primary and secondary technique efficacy rates, LTP rate, LTP-free survival (LTPFS), assisted LTPFS, overall survival (OS) and cancer-specific survival as well as identification of factors, associated with LTPFS and cancer-specific survival. Secondary study objectives included assessment of side effects and complication according to SIR classification [27, 36] .
Factors Affecting Oncologic Outcomes
Tumor-related (tumor size and location) and procedurerelated factors (minimal ablation margin) were analyzed as potential predictors of LTPFS.
Patient-related factors (lungs as first metastatic disease site) and prior therapies (prior lung or liver surgery, prior chemotherapy ± target therapy lines) were analyzed as potential predictors of cancer-specific survival.
Statistical Analysis
Statistical analysis methodology is described in Table 3 . Non-contrast-enhanced CT scan was obtained to depict the ablation zone as an area of ground glass opacity covering the target tumor with a minimal ablation margin of at least 5 mm uniformly around target metastasis
Minimal ablation margin (MM) measurement
It was measured on immediate post-procedure non-contrast-enhanced CT (Fig. 1) . MM was defined as the shortest distance between the ablated metastasis and the edge of the ablation zone. In confluent ablation zones and cases of bleeding obscuring the ablation zone the MM was not measured
Detection and management of pneumothorax
After ablation, chest X-rays were obtained for at least 2 h to detect pneumothorax prior to patients' release from the post-anesthesia care unit. Asymptomatic patients without pneumothorax and with no requirements for intravenous analgesia were discharged home on the same day. Patients with small asymptomatic pneumothoraces were admitted for overnight observation. Patients with larger, enlarging and/or symptomatic pneumothoraces were treated with thoracostomy and admitted to the hospital MWA microwave ablation
Results

Patient Population
Fifty patients with 90 colorectal lung metastases were treated in 60 MWA sessions. Twenty-eight (56%) of patients were women, and 22 (44%) were men with a mean age of 58.5 ± 13.2 years. Median follow-up for survivors was 25.6 months (range 12.8-80.6 months), and 29/50 (58%) of patients were followed for more than 2 years (Figs. 2, 3 ). At the time of initial diagnosis, 21/50 (42%) of patients had AJCC stage IV disease. Thirteen out of fifty (26%) of patients underwent MWA for disease progression after lung metastatectomy. Patient and tumor characteristics, biopsy timing as well as pre-MWA therapies are described in Tables 4 and 5 .
Technical Parameters and Technical Success Rate
Six out of fifty (12%) of patients received MWA in two separate sessions to treat bilateral lung metastases, with one patient requiring contralateral ablation delay for a week to allow persistent asymptomatic pneumothorax resolution. Ablation technical parameters are depicted in Table 6 . Technical success rate was 89/90 (99%): 1/90 (1%) of ablated tumors (3.2 cm in size, pleural based) maintained focal metabolic uptake on first post-MWA 18 F-FDG PET/ CT scan, consistent with residual tumor. Further tumor management is discussed in Sect. 7. MWA microwave ablation, LTP local tumor progression (Table 7) . LTP occurred at ablation margin or directly adjacent to the ablation zone in 6/9 (66%) LTPs. LTP within the ablation zone occurred in 3/9 (33%) of ablations: one stable in size cavitary ablation zone filled in, forming spiculated mass with pleural tethering, micronodularities and peribronchial thickening; another ablation zone showed considerable increase in solid component centrally; third ablation zone demonstrated gradual increase in size.
Primary Technique Efficacy Rate, LTP Rate and LTPFS
Median tumor size was 1 cm (range 0.3-3.2 cm). Primary technique efficacy rate was 81/90 (90%). Nine tumors
New focal FDG-avidity within the ablation zone consistent with LTP occurred in 4/9 (44%) LTPs, with SUV max ranging from 3.8 to 7.1. In all these cases, chest CT imaging also demonstrated suspicious increased ablation zone or focal nodularity adjacent to it. Fig. 2 Lung MWA ablation zone changes in 72-year old woman with metastatic colorectal cancer over 28-month follow-up period on cross-sectional CT, showing gradual constriction of ablation zone and no evidence of local tumor progression. After initial diagnosis, the patient underwent right hemicolectomy, adjuvant chemotherapy with 5-FU and leucovorin and was off-treatment with no evidence of disease for 18 months. A Pre-ablation enlarging lung nodule (from 0.9 to 1.6 cm) with rising CEA (from 5.8 to 11.6 ng/ml): lesion was considered metastatic, not biopsy-proven. Due to significant comorbidities (end-stage kidney insufficiency, coronary artery disease, diabetes, arterial hypertension and history of stroke), lung ablation was preferred to surgery. B Immediate post-MWA CT with ablation zone as ground glass opacity measuring 3.2 9 3.0 cm. C First post-MWA scan at 5 weeks, served as a new baseline for future comparisons. D Follow-up scan at 17 weeks. E Follow-up scan at 15.5 months; F follow-up scan at 28 months with constricted ablation zone and no evidence of local tumor progression. The patient was offtreatment after MWA with no evidence of disease elsewhere for 2 years, when the patient developed solitary biopsy-proven liver metastasis, treated with liver segmentectomy. The patient then was off-treatment with no evidence of disease elsewhere throughout the last follow-up
Minimal Ablation Margin
Median minimal ablation margin size was 5 mm (range 0-19 mm). Measurement of minimal margin was feasible in 86/90 (96%) ablations. In 4/90 (4%) ablations, it could not be calculated due to bleeding obscuring ablation zone (in 2%) or confluent ablation zones (in 2%). Minimal margin of at least 5 mm was achieved in 48/86 (56%) of measurable ablation zones. Fourteen out of eighty-six (16%) of metastases were pleural based, and minimal margin was considered 0 mm. Minimal margin size is described in Table 6 .
Prognosticators of LTPFS in Univariate Analysis
1. Minimal ablation margin size LTPFS was statistically significantly associated with minimal margin size (p \ 0.001) ( Table 7) . LTP was observed only for tumors ablated with minimal margin \ 5 mm, with LTP rate of 24% (Table 7) . 2. Tumor location (pleural vs. non-pleural based) Pleural-based metastases had 7.7 times higher LTP risk, compared to non-pleural-based metastases (p = 0.002). One-and 2-year cumulative LTP hazard for nonpleural versus pleural-based metastases was 4% and 7% versus 25% and 47%, respectively (Table 7 , Fig. 4 ). When analyzing non-pleural-based metastases alone, minimal ablation margin retained significance as a predictor of LTP on univariate analysis (p \ 0.001) ( Table 7 , Fig. 5 ). 3. Tumor size LTPFS was statistically significantly associated with tumor size (p = 0.001): LTP was only observed after MWA of tumors C 1 cm, with LTP rate of 19% (Table 7) . LTP rate of tumors C 1 cm in size was 41% when minimal margin was \ 5 mm, compared to 0% when minimal margin was C 5 mm (p = 0.0004, Fig. 6 ).
Overall and Cancer-Specific Survival
Median OS was 58.6 months, and median cancer-specific survival was not reached (Table 7) . Median OS for patients without LTP was 45.2 months and not reached for patients with LTP (HR = 0.63, p = 0.54). Three out of sixteen (19%) of deaths were not cancerrelated. They included sepsis and multi-organ failure in a patient with retroperitoneal abscess (4.7 months post-MWA); respiratory failure due to pneumonia (18 months post-MWA); and death of other cause 11 months post-MWA, with no evidence of oncologic disease in one [43] patient (negative whole body 18 F-FDG PET/CT 2 months before death). One out of sixteen (6%) of patients was lost to follow-up 13 months before death.
Management of LTP and Assisted LTPFS
Repeat MWA was offered in 2/9 (22%) LTPs and one residual tumor. Assisted LTPFS was not reached. Repeat MWA for residual tumor increased local tumor control with MWA from 1.5 to 23.7 months in one patient (after one repeat MWA; however, patient had subsequent LTP which was aggressively retreated with RFA using 3 electrodes and 4 overlapping ablations and no further LTP); from 8.83 to 75.5 months in second patient (two additional MWAs, no further LTP); and from 3.9 to 19.37 months in third patient (single additional MWA, no further LTP). Resulting secondary technique efficacy rate, accounting for all repeat MWAs, was 83/90 (92%). LTPs in the rest of patients were managed with: systemic chemotherapy in 4/9 (44%), lung resection in 1/9 (11%) and lung radiotherapy in 1/9 (11%).
Post-ablation Patient Management, Lung and Extrapulmonary Disease Progression
Six out f fifty (12%) of patients had no lung progression (inside and/or outside the ablation zone). Lung progression outside ablation zone was ablated in 14/41 (34%) of patients. Median overall lung progression-free survival was 8.8 months (Table 7 , Fig. 7 ). Thirty-two out of fifty (64%) patients had extrapulmonary disease progression post-MWA (with pulmonary progression in 29/32 (91%), and without in 3/32 (9%) patients).
Three out of fifty (6%) of patients were disease-free post-lung ablation and were off-treatment for 25, 65.4 and 74.9 months. Post-MWA therapies are presented in Table 8 .
Cancer-Specific Survival Prognosticators
Pre-MWA CEA level [ 10 ng/ml (p = 0.046, Table 9 , Fig. 8 ) and C 3 pre-MWA chemotherapy ± target therapy lines were associated with cancer-specific survival on univariate analysis (p = 0.02, Table 9 , Fig. 9) .
Prior lung or liver resection and lung as first site of metastatic disease were not associated with cancer-specific survival (Table 9) .
Small number of deaths and intermediate follow-up time precluded multivariate analysis of any predictors.
Side Effects and Complications
Incidence of side effects was 12/60 (20%). Minor complications rate was 23/60 (38%) and included pneumothorax, requiring thoracostomy. Major complications rate was 8/60 (13%); 75% of major complications included pneumothoraces requiring prolonged hospitalization (Table 10) . F-FDG PET/CT is a technique for PET/CT-guided ablation that permits target tumor localization and evaluation of treatment effectiveness. With this technique, standard diagnostic FDG activity dose of approximately 12 mCi (444 MBq) is administered in two aliquots: a 4-mCi (148-MBq) target/ imaging dose is administered 30-60 min before the ablation followed by an 8-mCi (296-MBq) administered immediately after the ablation with images obtained 30 min later. The higher dose overcomes background signal of the first lower dose and allows assessment of metabolic activity of the ablation zone and detection of residual hypermetabolic signal representing untreated residual tumor [39] PB pleural-based metastases, NPB non-pleural-based metastases, Cum. cumulative, SHR sub-hazard ratio 
Discussion
The LTP rate of 10% in this cohort compared favorably to reported 12-26% LTP rates in prior pulmonary tumor MWA series [33] [34] [35] 37] . This may be attributed to the relatively small tumor size and the creation of minimal margin C 5 mm in 56% of patients. We found a strong association between tumor size (p = 0.001), minimal ablation margin (p \ 0.001), lesion location (p = 0.002) and LTP. The small LTP number precluded multivariate analysis. All LTPs occurred in tumors C 1 cm, ablated with minimal margin \ 5 mm, with 41% LTP rate for tumors with both these factors (p = 0.0004). This observation supports the value of minimal margin as LTP predictor [7, 22, 31, 38, 39] . Tumor size remains a limiting factor for the widespread use of ablation regardless of energy used [23, [40] [41] [42] . Pleural-based tumors had more than seven times higher LTP risk. Minimal ablation margin remained significant predictor of LTP for non-pleural-based metastases.
One-, 2-and 3-year survival rates of 94, 84 and 60% compared favorably to reported ranges of 84-95, 56-72 and 35-65%, respectively [43] .
LTP did not affect overall survival (p = 0.54). The majority of patients received systemic chemotherapy and/ or targeted therapy post-MWA; more than a third of patients had subsequent lung ablation or lung resection for progression. Therefore, overall survival could not be solely attributed to lung ablation, but rather to the overall therapeutic management of oligo-metastatic disease. Local therapy for pulmonary metastases significantly prolonged 3-year survival in patients receiving adjuvant radiotherapy or ablation, compared to those treated with chemotherapy alone (88 vs. 33%, respectively) for pulmonary metastases [44] . Pre-MWA CEA level and number of prior chemotherapy and target therapy regimens predicted cancer-specific survival. CEA association with survival can be explained by CEA circulating cancer cell death inhibition and activation of cell adhesion-related molecules [45] that has been reported after metastasectomy of CRC lung metastases [46, 47] .
Thoracostomy rate of 38% rate is higher than what is reported after RFA (13-33%) [43] . This may be related to our clinical protocol of thoracostomy for any circumferential pneumothorax even in asymptomatic patients. The rate of moderate/large or enlarging pneumothorax was 28%, requiring prolonged hospitalization after 10% of procedures. The overall major complication rate of 13% is comparable to the 20% rate in prior lung MWA series [48, 49] .
Approximately a third of patients underwent MWA for progression of disease after lung metastatectomy and only 11% of were biopsy-proven, since radiological diagnosis of lung metastases in the setting of CRC is generally reliable [50] .
There currently is an ongoing debate on the impact of local therapy and pulmonary metastasectomy on survival in this population. Most of the evidence supporting complete removal of pulmonary metastases originated from surgical series of well-selected patients with favorable characteristics (a few or small size metastases) without any comparison to patients that were not resected [47, 51] . The lack of randomized data and comparative studies make conclusions about the impact of resection and locoregional therapies difficult [51] . Lung metastatectomy can improve survival; however, recurrence rates are high with repeat thoracotomy being associated with higher morbidity, whereas lobectomy offers no survival benefit when compared to limited sub-lobar or wedge resections [51] . Therefore, ablation could be advocated to be the preferable local therapy for small metastases that can be ablated with sufficient margins. The study had several limitations including its retrospective nature, the small number of patients and the intermediate length of follow-up, precluding long-term estimations. Another limitation is the lack of pathologic complete ablation confirmation, a common limitation of interventional oncology therapies. The impact of the MWA device choice on local tumor control was limited since 91% of tumors were ablated using the Neuwave device. Known genetic signatures and predictive biomarkers were not available for the entire cohort of patients and could not be assessed as potential factors impacting outcomes [39, [52] [53] [54] [55] .
To summarize, this work indicated the efficacy of MWA that compared favorably to prior results of thermal ablation in terms of local tumor control, local progression-free and overall survival. Factors associated with LTPFS and cancer-specific survival were identified and described. Further validation is certainly needed in larger studies with longer follow-up to better define the role of MWA in the management of CRC metastatic disease. Pleuritic pain 12 days after MWA with underlying pneumonia, empyema, bronchopleural fistula and dehydration requiring hospitalization for 10 days with intravenous antibiotics (combination of piperacillin and tazobactam), infusion therapy and analgesics (fentanyl and morphine). After discussion with thoracic surgery service, the underlying bronchopleural fistula was successfully managed with prolonged thoracostomy for 5 months in the outpatient setting without further sequelae.
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